Join us for an exciting discussion focusing on sequencing therapies in breast cancer with @JoshDragoMD @JuliaFoldiMD @sdent_cardioonc https://t.co/DlnQUp2YYL

#ASCO25 is around the corner, and it’s inspiring to see the growing momentum for #ILC research at major meetings. Just a few years ago, ILC had little to no visibility @ASCO, this year, 7 ILC abstracts will be presented. Here is a brief overview of each: 1. Macroscale Genomic

So proud of my mentor and friend, @oesterreichs, congratulations!! #ILC #SABCS24

A Huge Round of thanks to all of our colleagues who joined us in the #OncoAlert5k Homecoming Run Here in our Home Town of San Antonio Texas 🇺🇸 #SABCS24 @matteolambe 🇮🇹 @ErikaHamilton9 🇺🇸 @hoperugo 🇺🇸 @JaniceTNBCmets 🇺🇸 @DrSGraff 🇺🇸 @maryam_lustberg 🇺🇸 @double_whammied 🇺🇸

A little late, but October 15th was #LobularBreastCancer Awareness Day around the world and in PA, and we did our part in spreading awareness locally! So important to increase research in this area so we can do better for our patients!

Had a fantastic meeting at the #ILCsymposium in beautiful Leuven, Belgium organized by @ChristineDesme2 and her team! Lots to think about, and lot more progress that needs to be made! @oesterreichs @Adrianvlee

CDK4/6 inhibitors are transforming HR+/HER2- #BreastCancerTreatment. This review by @TMaggeMD, Sneha Rajendran, @breastoncdoc, & @JuliaFoldiMD highlights the benefits & limitations of these therapies & the emerging role of ribociclib & abemaciclib. 🗞️ https://t.co/iXc3ZTSH3j

Top 20 Breast Cancer Abstracts – #ASCO 2024 #bcsm #asco24

This year, I joined the Steel City Research Warriors team for the Komen Pittsburgh MORE THAN PINK Walk. Please support Komen's mission of ending breast cancer as we know it. Join us in Schenley Park for the walk on May 19th!

Registration for the Pittsburgh Annual Oncology Symposium: Experts and Evidence 2024 is open! Join us on August 23rd at the Sheraton Pittsburgh Hotel at Station Square by clicking this link: https://t.co/JWcKSMVL1X or scanning the QR code. Early-bird pricing valid until July 1st

1/ Breast cancer with chest wall metastases is a devastating disease with high unmet need. @TheTBCRC #TBCRC044 clinical trial led by Dr. Neelima Vidula @MGHBreastOnc and @hoperugo is currently enrolling patients.

Grateful and proud to speak about a topic near and dear to my heart alongside Ayaka Sugiura (@VanderbiltMSTP), @taliaswartz, and other inspiring women a in @NatureMedicine Comment piece today! @A_P_S_A #physicianscientists #doubledocs https://t.co/7YstR7eyuB

Great to see @SABCSSanAntonio catching up to other major conferences on this👏! They also added specifics on dedicated nursing spaces to their website - https://t.co/NFGbTYnSKA. Sad to see the 6 months age requirement... still don't know how I will attend with a 3-months old.

The upcoming #ILCSymposium is deadline for us to get papers on #lobular #breastcancer on #bioRxiv (and hopefully soon published) @Adrianvlee #1: @OsamaShirazShah used spatially-resolved transcriptomic, genomic, and single-cell approaches to study mixed ductal lobular brca 1/4🧵

A little late in sharing the good news that on my second try, I got the @NIH_LRP funded by the @theNCI this year! Only possible because of my amazing mentors from fellowship @YaleHemOnc and those @UPMCHillmanCC @MageeWomens and their true collaborative nature! #NIHLRP

🎙️ New CANCER BUZZ out now! Listen: https://t.co/emRAq9yYxD. In this episode #CANCER BUZZ speaks with Dr. Mariya Rozenblit about a new registry study for a rare form of #breastcancer. #podcast

Thank you, @UPMCHillmanCC for the support, and to @NRGonc for giving me this opportunity! Looking forward to meeting the other fellowship recipients this summer!

Are you living with oligometastatic #breastcancer? You may be eligible to participate in the @SusanGKomen supported CHLOE study which asks the question "can we cure oligometastatic HER2+ breast cancer?" Check out https://t.co/WECEIkD7xK or contact @MariyaRozenblit #BCSM

Dealing with private for-profit insurance companies, which often try to impede treatment for patients who desperately need it, has been by far the worst part of being a practicing oncologist. It's time we all have a say in this matter!

Congrats, @fredhow, such an important and huge analysis!